Heptares Therapeutics Appoints Dr Barry Kenny as Chief Business Officer
Barry has over 24 years’ research and management experience in the pharmaceutical and biotechnology industry, most recently as Vice President, Drug Discovery at Takeda Cambridge with overall responsibility for IND discovery. Prior to this, he was Commercial Director at Paradigm Therapeutics where he was responsible for several company-transforming deals, including the broad CNS collaboration with Takeda in 2005. He was also instrumental in the subsequent acquisition of Paradigm by Takeda in 2007.
Barry co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for Biofocus following its merger with CDD in 2001, establishing a wide range of international deals and collaborations. Before this, he was at Pfizer Central Research and was responsible for the successful discovery and progression of several drug candidates into clinical development. He also spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.